PET/CT与增强CT对于NSCLC放疗靶区勾画的价值及患者生存函数分析

Abstract
Figure/Table
References (22)
Related Citation (11)

Download: PDF (652 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the value of 18F-FDG PET/CT and enhanced CT in the delineation of radiotherapy target area for non-small cell lung cancer (NSCLC) and its effect on progression free survival time (PFS) and total survival time (OS). Methods Seventy-eight cases diagnosed as NSCLC treated with radiotherapy in Renmin Hospital of Wuhan University (“our hospital” for short) from January to December 2013 and the radiotherapy target area was delineated with enhanced CT that were enrolled in the enhanced CT group, while 78 NSCLC cases from January to December 2014 treated with radiotherapy in our hospital and the radiotherapy target area was delineated with 18F-FDG PET/CT, that were enrolled in the PET/CT group. The data of the two groups were preserved and compared. Adverse reaction rate of the two groups were compared. Follow-up results of 3 years and evaluation of the quality of life, PFS, OS were compared between the two groups. Results The total effective rate in the PET/CT group (32.05%) was higher than that in the enhanced CT group (14.10%), and the total effective rate of the PET/CT group was higher than the enhanced CT group (P ＜ 0.01). Adverse reaction rate and the incidence degree in the PET/CT group were lower than that in the enhanced CT group (P ＜ 0.05). The lungs V5, V20, V30 in the PET/CT group were better than the enhanced CT group (P ＜ 0.05). After 3 years of follow up, the quality of life in the PET/CT group was better than the enhanced CT group (P ＜ 0.01). PFS, OS in the PET/CT group were longer than the enhanced CT group (P ＜ 0.05). Detection rate of lesions via enhanced CT was lower than using PET/CT (P ＜ 0.05). The gross tumor volume (GTV) was smaller in the PET/CT group, and the maximum uptake value (SUVmax) was smaller in the PET/CT group than the enhanced CT group. Conclusion It is more precisely to use PET/CT to delineate the radiation field, that can improve the accuracy and reduce partial radiation quantity. It will reduce adverse incidence degree and improve the prognosis, so as to extend PFS and OS.

Key words： Non-small cell lung cancer Radiotherapy Fluorodeoxyglucose F18 Positron emission tomography

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Shan HUANG Jie

Cite this article:

CHEN Shan HUANG Jie. The evaluation of PET/CT and enhanced CT in the target area of NSCLC radiotherapy and the analysis of patient survival function[J]. 中国医药导报, 2018, 15(25): 132-136.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I25/132

[1] 宋跃峰，孙军娜，王玉分.PET-CT在肺癌淋巴结清扫术中的指引作用[J].中国医学工程，2017，25（10）：80-82.
[2] 张曙光，宋平平，张百江.PET/CT在肺癌治疗应用价值研究的现状[J].中华肿瘤防治杂志，2013，20（5）：392-395.
[3] 范丽，望云，夏艺，等.PET/MRI在肺癌中的潜在临床应用价值[J].国际医学放射学杂志，2016，39（3）：285-290.
[4] 高世乐，董六一，王崇，等.全身PET/CT断层显像联合肿瘤标志物检测在肺癌诊断及鉴别诊断中的临床意义[J].安徽医药，2015，19（4）：702-705.
[5] 邵亭亭，于丽娟，李迎辞，等.PET/CT密度比与摄取比判断肺癌纵隔淋巴结转移的研究[J].中国肺癌杂志，2015， 18（3）：155-160.
[6] 秦露平，程木华.PET-CT在肺癌鉴别诊断中的研究进展[J].新医学，2015，46（11）：713-718.
[7] 石远，牛奕.美国国家综合癌症网非小细胞肺癌治疗指南2007年第一版介绍[J].中华肿瘤杂志，2007，29（10）：799-800.
[8] 宋颖秋，王天禄，党军，等.PET/CT下合并肺不张非小细胞肺癌的治疗结果和预后分析[J].中国肿瘤，2017，26（1）：68-72.
[9] 张正福，李兰涛，王海燕，等.HRCT与PET/CT相结合对孤立性肺癌结节和结核球的鉴别诊断价值[J].临床放射学杂志，2013，32（12）：1727-1729.
[10] 张召奇，赵新明，王建方，等.18F-FDG PET/CT诊断非小细胞肺癌纵隔淋巴结转移[J].中国医学影像学杂志，2014，22（4）：293-296.
[11] 李兰涛，张正福，刘少东，等.HRCT并PET/CT对周围型肺癌和结核球鉴别诊断[J].青岛大学医学院学报，2014， 50（2）：167-169.
[12] 迪丽努尔·乌甫尔，克丽别娜·吐尔逊，李晗.PET/CT、支气管镜及联合肿瘤标记物在肺癌中的诊断价值[J].新疆医科大学学报，2017，40（2）：181-183，187.
[13] 陈万青，李贺，孙可欣，等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志，2018，40（1）：5-13.
[14] 王丽.中国原发性肺癌诊疗规范（2015年版）解读[J].世界临床药物，2016，37（7）：433-436.
[15] Travis WD，Asamura H，Bankier AA，et al. The IASLCLung Cancer Staging Project：Proposals for Coding TCategories for Subsolid Nodules and Assessment ofTumor Size in Part-Solid Tumors in the ForthcomingEighth Edition of the TNM Classification of LungCancer [J]. J Thorac Oncol，2016，11（8）：1204-1223.
[16] 张龙敏.PET/CT检查联合肿瘤标志物检测诊断肺癌的意义[J].内蒙古医学杂志，2017，49（10）：1200-1201.
[17] 梁萌，郑容.PET/CT在非小细胞肺癌放射治疗中的应用现状[J].中国医学影像技术，2014，30（8）：1276-1279.
[18] 吕律，吴宁.~(18)F-FDG PET/CT全身肿瘤代谢负荷参数在非小细胞肺癌患者预后评估中的应用[J].癌症进展，2016，14（1）：26-28，31.
[19] Kamiyama H，Sakamoto K，Niwa K，et al. Unusual False- Positive Mesenteric LymphNodes Detected by PET/CT in a Metastatic Survey ofLung Cancer [J]. Case Rep Gastroenterol，2016，10（2）：275-282.
[20] 包睿智，斯琴高娃.18F-FDG PET/CT在非小细胞肺癌放射治疗靶区中的应用[J].当代医学，2017，23（12）：181-184.
[21] 左文伟，陈灿，张艳玲.肺癌三维适形放疗联合TP方案应用于非小细胞肺癌的回顾性分析[J].癌症进展，2018， 164（4）：436-438.
[22] Fried DV，Mawlawi O，Zhang L. Potential Use of（18）F-fluorodeoxyglucose Positron Emission Tomography-Based Quantitative Imaging Features for GuidingDose Escalation in Stage Ⅲ Non-Small Cell Lung Cancer [J]. Int J Radia Oncol Biol Phys，2016，94（2）：368-376.